The late effects.-The late effects of the administration of an anisthetic can be studied in small animals by making histological studies, and by various other methods. Compounds which are related to chloroform, however distantly,are naturally suspected of having a toxic action on the liver or on the kidney, and a thorough study is necessary to clear them of this suspicion.
Application to man.-When the pharmacological tests have given satisfactory results, there comes a point at which a new anwsthetic should be tested on man. Opinions differ about the stage at which clinical trials should begin, and these differences are of sufficient importance to deserve discussion.
My own view is that the essential features of the pre-clinical testing are two. One is that the anaesthetic should be used during full-scale surgical operations on dogs, and should be found to allow prompt and satisfactory recovery. The other is that the anaesthetic should be shown to be free from a toxic action on the liver, kidney and other organs.
But someone else may have a different view, insisting that the anresthetic should not be tried in man until the details of the fate of the anesthetic have been thoroughly determined. It might be suggested, with reference to halothane, for example, that atoms of fluorine may remain in the body, causing pathological changes after a period of two or three years, and that we cannot yet be sure whether the use of halothane will not have serious consequences long after its administration. This is an extreme view, which can be held only by very few if we consider the widespread use which halothane has already achieved.
When we reflect on the large number of important new remedies which have been introduced as a result of tests in animals and which have been shown to have a similar action in man, it seems to me difficult to give any consideration to the idea that a new anwsthetic which behaves satisfactorily in mice and in dogs may conceivably be dangerous for man. Almost all the specific remedies right back to diphtheria antitoxin have been worked out on animals, and have been shown to be effective in man. Toxic effects such as agranulocytosis, aplastic anemia and hepatic necrosis, of the occurrence of which animal tests gave no hint, have certainly been seen in man but these have been for the most part effects following repeated use. An anesthetic is not administered repeatedly to the same person. It therefore seems to me that the initiation of clinical trials after the completion of a full investigation on animals offers no great problem of responsibility.
Clinical Tests of New Drugs
By RONALD WOOLMER, F.F.A. R.C.S. London MY approach to the testing of drugs is that of a clinical anxesthetist, which is bound to be a little different from that of the pharmacologist. Relationships with patients are concerned with considerations very different from those applying to animals; and the testing of new drugs may raise ethical problems of considerable difficulty.
The questions to be asked are these:
(1) What tests must I require to be made, on animals, before I try a new drug on humans?
(2) To what extent may species differences invalidate these tests?
(3) What risk is there that harm will befall the patient in spite of the best that I can do in screening?
In trying to define what is ethical, it is easy to draw up a code so strict that no experimentation at all would be permissible. That would reduce human pharmacology and therapeutics to a theoretical science. At the other extreme is the attitude which can be expressed like this: "in the anwsthetic room and the operating room we have unrivalled opportunities for the practice of applied pharmacology in the human. Let us exploit them to the full." Obviously, the correct attitude lies between these two extremes, and most anesthetists would put it nearer to the first than to the second. Hence, before human experimentation is permissible with new compounds screening in animals must be as thorough as we can make it.
What is this screening expected to do? First, clearly, to enable us to reject compounds which are toxic to the animals used, and hence to homo sapiens. But of course all drugs that are active are "toxic" if we give enough. So we have to define more closely what we mean by toxic; and to do this we make use of the therapeutic ratio, the ratio of the effective dose to the lethal dose, to which Professor Burn has already referred. We have to assume that the therapeutic ratio is about the same for man as it is for animals. If this assumption errs in one direction we may be led to reject a drug which could be useful: if it errs in the other we may endanger the lives of our patients. It is, therefore, pertinent to ask how valid is this assumption? For the general anesthetics, as Professor Burn has said, there is a considerable body of evidence in favour of it; but anmsthetists are not concerned only with general anesthetics. Indeed, with the obvious exception of halothane, the drugs added to the anaesthetist's repertoire during the last ten years have, in the main, not been general anesthetics, but have belonged to pharmacological groups in which a species difference in therapeutic ratio may be expected. Careful comparisons have, therefore, to be made. If the comparison is between man and only one other species of animal, we should not put much faith in it. A lot depends, too, on what species of animal. The fact that a drug had a high therapeutic ratio in a frog would not embolden me to give it freely to a man. Should we, therefore, confine our screening to mammals and, pursuing the idea to its logical conclusion, even to primates ? If we were to do this, experiment would be brought almost to a standstill; and the little that still went on would probably be no safer. For practical reasons, we have to accept the use of the laboratory animals: mice, rats, rabbits, guinea-pigs, cats and dogs: with more exotic creatures such as goats, monkeys, pigeons and goldfish forming a small minority. But we know that these species react differently to the relaxant drugs, for instance; and Professor Burn has reminded us that the cat's reaction to the opiates is very different from that of humans.
We know, too, that a twist of a molecule can profoundly alter its pharmacological effect, so that a narcotic, for instance, can be turned into a convulsant. It seems entirely possible, therefore, that subtle differences in enzyme chemistry existing between species might turn a harmless metabolite into a deadly one.
It seems to me that the answer to the second question is that the operation of species differences makes it impossible to be quite sure that a drug which has been shown to be safe for one-or even for several-species will be safe for man.
Safety, moreover, is not the only consideration when testing drugs for possible use in man. Side-effects must also be considered. It is usually possible to establish a technique for measuring the main effect of a drug: loss of reflexes, response to graded stimuli, fall of blood pressure, and so on; but side-effects are usually subjective and hence, in animals, immeasurable. By side-effects I mean, in this context, such things as nausea, faintness, disorientation, sleepiness, restlessness, euphoria, and liability to addiction. It is easy, in aniimal experiments, to draw up a series of dose-response curves and to put a number of analgesic drugs in order of potency; but even if this order should hold good for man, it could be that a drug with good analgesic powers exerted side-effects which rendered it useless as a therapeutic agent but of which the animal experimenter had perforce remained unaware.
We must realize, therefore, that animal screening-though it is unthinkable that it should not be conscientiously applied-has certain limitations. After the screening process has been completed there comes the next step of giving it to a human. This step must be taken by the clinician, and he has to bear the responsibility of it. Humans, in this context, may be of two kinds: healthy volunteers and hospital patients. In general, the former are not very much used, at any rate for active compounds. It is a nuisance to have one's laboratory boy out for the count; and medical students can put up with only so much. Moreover, for testing many remedies, it is essential to have a subject who is not healthy. It is obvious that some therapeutic agents can be tested only on patients suffering from reversible pathological conditions. But if we use patients, we are faced with the difficult problem of consent. Strict ethical considerations require that we should always obtain the consent of a patient before any experimental procedure and that for this the details and purpose of the procedure, and the risks it entails, should be fairly put to him. But things are often not so clear cut as this. If I decide to give a dose of a drug which is outside the recognized therapeutic range, or to use familiar drugs in an unfamiliar combination, or to test a new vaporizer or absorber, is that a matter for which consent should be obtained? And the patient is not the only person to be consulted. Anesthetists seldom have charge of patients. Some other clinician, usually the surgeon, is involved as well. When we are cautiously trying a new relaxant, and the abdominal muscles grip the surgeon's hand so tightly that he can't move it, do we explain the position and ask him to bear with us, or do we say: "Don't worry. He'll be all right in a minute," and quickly slip in 50 mg. of suxamethonium? That depends on many factors; but obviously it is quite wrong to do anything which may endanger the patient, or in any way affect his welfare, without the consent of the surgeon who bears most of the responsibility for him. Most people would agree, too, that one should not embark on human experiments unless the information which they will yield can be obtained in no other way; and unless they can be expected to yield a rich therapeutic reward. Mere scientific curiosity, laudable though that is, is not sufficient justification.
But given a case in which the goal is unassailable, and in which only human experimentation will suffice, one has to be mindful of the risks involved, and of the consequences of failure. In the history of therapeutics a number of instances may be found in which risks were run, with resultant benefit to mankind. The first vaccination might have been a failure and might have resulted in injury to the patient. In that event, immunology would have suffered a severe setback. For reasons which are obvious, it is difficult to find records of experimental work in which patients have been subjected to grave risks; but there are many examples of a research worker accepting grave risks when acting himself as the experimental subject.
The great John Hunter inoculated himself with gonorrhoeal pus while investigating venereal disease. Carroll and Lazear allowed themselves to be bitten by mosquitoes carrying yellow fever, and Lazear died of the disease. Pettenkofer drank a culture of virulent cholera bacilli to show his contempt for Koch. August Bier, in 1898, had 2 ml. of 1 % cocaine injected into his subarachnoid space, and got off with nothing worse than a headache. More recently, Pask submitted to considerable discomfort, and some risk, in investigating life jackets. But of course work with the experimenter as the subject is governed by a different set of standards from those that can be applied to patients. Human experimentation, as distinct from work with animals, involves special hazards, and therefore requires special precautions and imposes special responsibilities.
However conscientious we are, it is difficult or impracticable to make our preliminary tests so thorough that we can rule out even the remotest complications. Nine or ten years ago Myanesin (mephenesin) was introduced as a muscle relaxant for intravenous use. Animal screening had been apparently adequate, and before the drug came into my hands it had been given to a number of patients with no untoward effects. The third patient to whom I gave it, for an interval appendicectomy, developed a lower nephron nephrosis, almost certainly as a result of intravascular hmmolysis, and died. Other cases of intravascular heemolysis were later reported. It would, I suppose, have been possible to avoid this by animal tests for this specific purpose; but no one had entertained the possibility. A few years later, Efocaine was introduced as a longlasting local analgesic and for a time it was much used, by perineural injection, to lessen postoperative wound pain. It was not until thousands of administrations without trouble had been reported that its propensity for destroying peripheral nerves, and for tracking back and damaging the spinal cord, was realized. Here again, animal work done with this point in mind would have prevented trouble, but it is easy to be wise after the event, and nobody thought of it at the time. It seems then that the answer to my third question: "What risk is there that harm will befall the patient in spite of the best that I can do in screening?" is that there is a small but definite risk.
The most difficult field of applied pharmacology which can concern anesthetists is the evaluation of analgesic drugs; and there are several reasons why animal experimentation, in this field, is unsatisfactory. One reason is that it tells us nothing of side-effects as I have already mentioned. Another point, emphasized by Beecher, is that, in all experiments which can be devised, a reflex response is used as the criterion or end-point. But we have no means of knowing whether pain relief and depression of reflex activity in animals go hand in hand.
Hence for this work, though animal screening is an indispensable preliminary, the subject must be man. And this is where our difficulties start. There seems no doubt that pain produced in the laboratory is different from pain of pathological origin-from the pain of the hospital patient and responds differently to drugs, so that hospital patients, with pain, constitute perhaps the only satisfactory material. In this field, more than in any other, we are perplexed by the placebo response; and if our evaluation is to be worth anything at all we have to arrange a double blind trial with three substances given in random order: the drug under test, an analgesic whose characteristics are known, and a placebo.
Even then we have to rely on subjective impressions, often relayed to us at second hand by people who may be biased or careless; and we have to find patients who really have pain. Then we find ourselves involved in the difficult ethical problem of palming off, on a patient we know to be in pain, a preparation we know to be devoid of pharmacological action. We can derive some comfort, in this dilemma, from the knowledge that in most series the placebo alone has conferred relief of pain in about one-third of the cases. 
